PSNL - Personalis GAAP EPS of -$0.61 misses by $0.05 revenue of $18.9M beats by $1.55M

2023-05-03 16:40:37 ET

• Personalis press release ( NASDAQ: PSNL ): Q1 GAAP EPS of -$0.61 misses by $0.05 .
• Revenue of $18.9M (+24.1% Y/Y) beats by $1.55M .
• Cash, cash equivalents, and short-term investments of $148.9 million as of March 31, 2023

• Personalis expects the following for the second quarter of 2023:

• Total company revenue of $16 million to $17 million vs$18.05M Consensus

• Revenue from pharma tests, enterprise sales, and other customers of $13 million to $14 million

• Revenue from population sequencing of approximately $3 million

• Personalis expects the following for the full year of 2023:

• Total company revenue in the range of $68 million to $72 million vs $70.46M Consensus
• Revenue from pharma tests, enterprise sales, and all other customers in the range of $59 million to $63 million
• Revenue from population sequencing of approximately $9 million
• Net loss of approximately $103 million, reduced from $113 million in 2022 due to realization of headcount reduction savings, partially offset by investments in clinical evidence generation and non-cash depreciation expense for the new facility
• Cash usage of approximately $75 million, reduced from $119 million in 2022

For further details see: